There are currently 140 active clinical trials seeking participants for Major Depressive Disorder research studies. The states with the highest number of trials for Major Depressive Disorder participants are California, Florida, Texas and New York.
Ketamine-Assisted Mindfulness-Based Cognitive Therapy for Depression: A Pilot Study
NCT05950711
Recruiting
The purpose of this study is to assess the feasibility of combining IV ketamine, a rapid acting antidepressant, with a course of Mindfulness-Based Cognitive Therapy (MBCT), for the initial and maintenance treatment of depression.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
07/10/2023
Locations: Harding Hospital, Columbus, Ohio
Conditions: Major Depressive Disorder
Register for Updates
Transcranial Magnetic Stimulation for Youth With Treatment-Resistant Major Depressive Disorder
NCT05652465
Recruiting
Background: Major depressive disorder (MDD) is one of the most impairing medical conditions in the world. Medication and some kinds of talk therapy are standard treatments for teens with MDD, but these do not work well for everyone. Transcranial magnetic stimulation (TMS) has been approved to treat MDD in adults. TMS might help adolescents, too. Objective: To test TMS combined with cognitive behavioral therapy (CBT) in teens with MDD. Eligibility: People aged 13 to 17 years with MDD that ha... Read More
Gender:
All
Ages:
Between 13 years and 17 years
Trial Updated:
06/20/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Major Depressive Disorder
Register for Updates
Mindfulness Engaged Neurostimulation for Depression
NCT06399406
Recruiting
Repetitive Transcranial Magnetic stimulation (rTMS) is an FDA-approved therapy for treatment resistant depression (TRD) that involves brief magnetic stimulation pulses on the dorsolateral prefrontal cortex (DLPFC) brain region. But studies of rTMS alone show remission rates of ~30%. Additionally, rTMS has not been shown to improve cognitive functioning that may be an independent factor predicting treatment success. This study will develop a novel multimodal treatment, which combines intermittent... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/20/2024
Locations: University of California San Diego, La Jolla, California
Conditions: Depression, Treatment Resistant Depression, Major Depressive Disorder, Depressive Disorder
Register for Updates
A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder
NCT06267846
Recruiting
To evaluate the efficacy, safety, and tolerability of NBI-1070770 compared to placebo on improving symptoms of depression in participants with major depressive disorder (MDD).
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/20/2024
Locations: Neurocrine Clinical Site, Little Rock, Arkansas +12 locations
Conditions: Major Depressive Disorder
Register for Updates
PD, PK, and Safety of ALTO-203 in Patients With MDD
NCT06391593
Recruiting
The goal of this clinical trial is to determine the pharmacodynamic effects of ALTO-203 in patients with MDD in a randomized, placebo-controlled, single-dose crossover treatment period. Additionally, safety, tolerability, and PK will be assessed in a subsequent randomized placebo-controlled multi-dose parallel-group treatment period of 28 days. Participants will complete subjective response questionnaires and perform cognitive tasks during the single-dose period, in which participants will rece... Read More
Gender:
All
Ages:
Between 25 years and 64 years
Trial Updated:
06/19/2024
Locations: Site 4058, Tucson, Arizona +13 locations
Conditions: Major Depressive Disorder, Anhedonia
Register for Updates
Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression
NCT06419608
Recruiting
The purpose of this study is to determine the efficacy and safety of BHV-7000 in participants with Major Depressive Disorder (MDD)
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/18/2024
Locations: Reverie Mind, LLC, Chandler, Arizona +49 locations
Conditions: Major Depressive Disorder
Register for Updates
Predicting SSRI Efficacy in Veterans With PTSD
NCT04183205
Recruiting
This is a research study to examine the effectiveness of a brief screening method that may predict which people with posttraumatic stress disorder (PTSD) or depression are most likely to show a positive response to selective serotonin reuptake inhibitor (SSRI) medications. Participants will be recruited over approximately 5.25 years, until at least 94 participants complete the 17 week study.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/17/2024
Locations: VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston, Massachusetts +1 locations
Conditions: Posttraumatic Stress Disorder, Major Depressive Disorder
Register for Updates
HypErthermia as an Additional Treatment for the Biology and Experience of Depression: Study 2
NCT05708976
Recruiting
This randomized two-arm intervention trial administers 8 weekly cognitive behavioral therapy (CBT) sessions and 4 bi-weekly active whole-body hyperthermia (active WBH) sessions or 4 bi-weekly sham WBH sessions to adults aged 18 years or older with major depressive disorder (MDD).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: University of California San Francisco, San Francisco, California
Conditions: Major Depressive Disorder, Depression
Register for Updates
Antidepressant Effects of TS-161 in Treatment-Resistant Depression
NCT04821271
Recruiting
Background: Major depressive disorder (MDD) is a common, chronic mental illness. It can take weeks to months for antidepressants to work. Researchers want to test a new drug that might act more rapidly. Objective: To see if TS-161 will improve symptoms of depression in people with MDD. Eligibility: Adults ages 18-65 with MDD without psychotic features. Design: Participants will be screened under a separate protocol. They will have blood tests. They will complete surveys about their sympto... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/15/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Major Depressive Disorder, Treatment-Resistant Depression, Depression
Register for Updates
Diet and Depression
NCT06252701
Recruiting
This study is a pilot open label crossover trial to assess the feasibility and acceptability of reducing ultra- processed foods (UPF) in a personalized manner from the diets of patients with major depressive disorder who eat a large percentage of UPF.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
06/14/2024
Locations: University of California, San Francisco, San Francisco, California
Conditions: Depression, Major Depressive Disorder, Weight Gain, Obesity, Metabolic Syndrome
Register for Updates
Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder
NCT06058039
Recruiting
This randomized, double-blind, placebo-controlled, multicenter study will evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 35 days), and a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and mee... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/13/2024
Locations: Neumora Investigator Site, Cerritos, California +15 locations
Conditions: Major Depressive Disorder
Register for Updates
Study to Evaluate the Effects of Oral NMRA 335140 Versus Placebo in Participants With Major Depressive Disorder
NCT06029426
Recruiting
This is a randomized, double blind, placebo controlled, multi-center study to evaluate the effects of NMRA 335140 (formerly BTRX 335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 28 days), and a 6-week Treatment Period (during which participants will receive either NMRA 335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/13/2024
Locations: Neumora Investigator Site, Huntsville, Alabama +62 locations
Conditions: Major Depressive Disorder
Register for Updates